Skip to content
Education Training, Medical Health Aged Care

New CDU health teaching and research facility marks construction milestone

Charles Darwin University 2 mins read

Charles Darwin University’s (CDU) new $25.8 million Centre for Better Health Futures has marked a significant construction milestone. 

The new health teaching and research facility celebrated its 'topping out' in Darwin today, with the installation of the Centre’s roof allowing construction to continue throughout the Wet Season.

Once complete, the 3,684 square-metre, three‑storey building will deliver practical learning facilities along with laboratory environments and research infrastructure.

Built by SHAPE Australia, the Centre will include a simulated emergency department and 12-bed hospital ward, giving students the best possible preparation to join the growing Northern Territory health workforce.

Preclinical and clinical simulation environments will also be equipped with virtual reality and mobile technologies that can be used by students at CDU campuses across the Territory - including Nhulunbuy, Katherine and Alice Springs. 

CDUs Pro Vice-Chancellor Faculty of Health, Professor Dominic Upton, said the new building would be a “game changer” for educating health and medical professionals in the Territory.  

“CDU students will have access to state-of-the-art teaching resources and real-world clinical facilities, ensuring they are well placed to make a significant contribution to the Territory workforce on their graduation,” Professor Upton said.

“Bringing all professions together - from medicine, nursing, and allied health sciences, the focus on interprofessional working will enhance the excellence of their education and ensure students are well set-up to enter the professional workforce.

"With scenarios and resources specifically designed for the Territory’s unique and challenging environment, this new facility will be the jewel in the crown CDUs Faculty of Health."

In total, $25.8 million has been invested in the Centre, including $10 million from the Federal Government and $15.8 million from CDU.

Federal Minister for Northern Australia, the Hon Madeleine King MP, said “people living in the Top End deserve access to world-class education and top-quality healthcare” and that the Centre will deliver both. 

“This project, which was supported by a $151.5 million loan from the Northern Australia Infrastructure Facility is another example of the Albanese Government delivering economic, social and community outcomes for the NT,” Minister King said. 

Federal Member for Solomon and Special Envoy for Northern Australia, Luke Gosling OAM MP, said the Centre for Better Health Futures is, "all about building the Territory."

"The Territory needs more health care workers, and this Centre is another step towards that," Mr Gosling said. 

"It builds on the numerous initiatives at CDU supported by the Albanese Government including the new Medical School, the recently opened CDU City Campus – Danala, and CDUs recently expanded allied health services."

SHAPE Australia’s General Manager – Northern Territory, Nicholas Mills, said the topping out is a “significant achievement” for the project and the hundreds of local workers.

“Reaching the topping out milestone is a significant achievement for our construction team and a testament to the hard work and dedication of the more than 250 local Territorian workers across our 35 subcontractors,” Mr Mills said.

“We are on track and making excellent progress towards the completion of this state-of-the-art facility, and this crucial phase allows us to proceed with interior work throughout the Wet Season.”

The Centre for Better Health Futures is on track for completion by mid-2025.  


Contact details:
Alyce Mokrzycki
Media and Communications Officer
 
Marketing, Media and Communications
E: [email protected]
W: cdu.edu.au
 
CDU logo

Media

More from this category

  • Medical Health Aged Care
  • 16/06/2026
  • 22:47
Optimi Health Corp.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber SchemeVANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products…

  • Medical Health Aged Care
  • 16/06/2026
  • 14:30
Dementia Australia

Brisbane comes together for people impacted by dementia

Brisbane community members tied up their laces and showed up in force last weekend for the 2026 Brisbane Memory Walk & Jog - throwing their support behind people impacted by dementia whilst getting active to improve their brain health. More than 1,470 people walked, ran and jogged to the finish line to raise an impressive total of $195,098. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, volunteered and raised vital funds for the cause. “There was an incredible turnout from the Brisbane community this year yet again, in support of the many people impacted by…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 16/06/2026
  • 09:51
ENA Respiratory

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

Melbourne, Australia, 15 June 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, announces today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for two patent applications notably a composition-of-matter patent and method-of-use for its Toll-like receptor 2 (TLR2) therapies. A composition-of-matter patent (US 17/622,451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary disease (COPD) (US 16/495,829, "Methods of treating rhinovirus-mediated exacerbations of COPD…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.